摘要
目的:评价顺铂、卡铂和足叶乙甙联合方案(CCE)的疗效、耐受性和毒性反应。方法:以CCE方案治疗非小细胞肺癌(NSCLC30例)。化疗方案以卡铂(CBP)200mg/m2静脉滴注,第一天;顺铂(DDP)30mg/m2静脉滴注,第3-5天;足叶乙甙(VP-16)100mg/m2静脉滴注,第1-5天;每28天重复。结果:全组共完成任务16个周期,中位周期数4.0,有效率40%。中位生存期9.2,一年生存率34%。常见的毒副反应为骨髓抑制,发生率为86.67%.其中I度23.33%;II度36.67%;III度26.67%;IV度过3.33%。胃肠道反应较轻,I度43.33%;II度33.33%;III度17.78%。结论:CCE方案患者的耐受良好,毒副反应较轻,初步疗效令人满意,值得进一步研究。
Purpose To evaluate the effect, tolerabilily and toxic-side reactions of combined carboplatin and cisplatin with etopside in advanced non-small-cell lung cancer. Methods From June,1998 to May 2000, 30 cases with advanced non-small-cell lung cancer were treated by combined carboplatin[200mg/m2intravnously (IV) on day1] and Cisplatin (30mg/m2 IV on day 3～5) and etopside (100mg/m2IVon day 1～5).The treatment was repeated every 3～4 weeks . Results 16 cycles were completed in the whole group . Median cycles was 4 . The overall response rate was 40%.The median survival time was 9.2 months . The 1-year survival rate was 34%. Elosuppression was the main toxicity , The overall response rate was 86.67%.Conclusions Our rewults indicate that combined carboplatin and cisplatin with etopside regimen is effective for advanced non-small-cell lung cancer.
出处
《安徽卫生职业技术学院学报》
2002年第1期34-35,共2页
Journal of Anhui Health Vocational & Technical College
关键词
非小细胞肺癌
卡铂
顺铂
足叶乙甙
联合化疗
non-small-cell lung
carboplatin
cisplatin
etopside
combined chemotherapy
